Replies to post #232983 on Innovation Pharmaceuticals Inc (IPIX)

[nerby]

I think that what we and even IPIX know today about the full extent of potential future benefits, indications, and revenue streams for Brilacidin is about half of the tail of the whale. A powerful antibiotic that recognizes and efficiently kills predatory non-human cells so fast that resistance - rapid bacterial compensation and evolution - is unlikely. Incredibly this same molecule can then shed its armor, put on its anti-inflammatory cardigan, and nurture human cells back to health, even human cells of highly disparate function.

I keep my thoughts on Prurisol close to my chest. The Aspire financing agreement clearly shows IPIX's internal guess on Prurisol success.

Kevetrin, my man. Hardly mentioned by IPIX shareholders these days, nor much by IPIX management. The issue of course is that Kevetrin is exclusively a cancer application candidate, and those are spendy, and it will take $50 - $100 million and another 2 - 4 years to prove out Kevetrin's full value. I can wait. I'll grow old and wealthy with Kevetrin.